The value of innovation: association between improvements in survival of advanced and metastatic non-small cell lung cancer and targeted and immunotherapy

The value of innovation: association between improvements in survival of advanced and metastatic non-small cell lung cancer and targeted and immunotherapy

Abstract Background Significant improvements in mortality among patients with non-small cell lung cancer (NSCLC) in the USA over the past two decades have been reported based on Surveillance, Epidemiology, and End Results (SEER) data. The timing of these improvements led to suggestions that they res...

Full description

Bibliographic Details
Main Authors: Sreeram Ramagopalan, Thomas P. Leahy, Joshua Ray, Samantha Wilkinson, Cormac Sammon, Vivek Subbiah
Format: Article
Language:English
Published: BMC 2021-09-01
Series:BMC Medicine
Subjects:
Lung cancer
NSCLC
Immunotherapy
Innovation
Targeted therapy
Online Access:https://doi.org/10.1186/s12916-021-02070-w

Internet

https://doi.org/10.1186/s12916-021-02070-w

Similar Items